Genomes and Genes
Affiliation: Institute of Cancer Research
- Delivering cancer genetics services--new ways of workingRos Eeles
Cancer Genetics Unit, Orchard House, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK
Fam Cancer 6:163-7. 2007
- Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyElizabeth K Bancroft
Cancer Genetics Unit and Academic Urology Unit, Royal Marsden NHS Foundation Trust, London, UK Oncogenetics Team, Institute of Cancer Research, London, UK
Eur Urol 66:489-99. 2014....
- A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancerZ Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
Br J Cancer 100:426-30. 2009....
- Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotypeA Mitra
Translational Cancer Genetics Team, Institute of Cancer Research, Surrey, UK
Br J Cancer 98:502-7. 2008..Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial...
- Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosisS M Edwards
Oncogenetics team, Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5PT, UK
Br J Cancer 103:918-24. 2010..The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours...
- Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriersAntonis C Antoniou
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK
Breast Cancer Res 14:R33. 2012..2)...
- Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriersAna Teresa Maia
Cambridge Research Institute CRUK, Li Ka Shing Centre, Cancer Research UK, Robinson Way, Cambridge, CB2 0RE, UK
Breast Cancer Res 14:R63. 2012..We have previously reported that BRCA2 shows differential allelic expression and we hypothesize that the known variable penetrance of BRCA2 mutations might be associated with this mechanism...
- Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) familiesJoan E Bailey-Wilson
Inherited Disease Research Branch, National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA
BMC Med Genet 13:46. 2012..Current evidence suggests that genetic linkage to prostate cancer has been found on several chromosomes including the X; however, identification of causative genes has been elusive...
- Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping arrayRosalind A Eeles
The Institute of Cancer Research, Sutton, UK
Nat Genet 45:385-91, 391e1-2. 2013..7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies...
- Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
- Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening testsMariëlle Ae Nobbenhuis
Department of Gynaecological Oncology, The Institute of Cancer Research and The Royal Marsden Foundation Trust, Cotswold Road and Fulham Road, SW3 6JJ, London, UK
Hered Cancer Clin Pract 9:11. 2011..abstract:..
- Unusual presentation of Lynch SyndromeVeronica Pcc Yu
Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK
Hered Cancer Clin Pract 7:12. 2009..We describe a family of Lynch Syndrome with an hMLH1 mutation, that harbours an unusual tumour spectrum and its diagnostic and management challenges...
- Exploring the link between MORF4L1 and risk of breast cancerGriselda Martrat
Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
Breast Cancer Res 13:R40. 2011..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens...
- Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriersLogan C Walker
Division of Genetics and Population Health, Queensland Institute of Medical Research, Brisbane, Australia
Breast Cancer Res 12:R102. 2010..In this study, we evaluated 24 SNPs tagged to 14 candidate genes derived through a novel approach that analysed gene expression differences to prioritise candidate modifier genes for association studies...
- Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS studyDeborah J Thompson
Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 11:R80. 2009....
- Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controlsImogen Locke
Translational Cancer Genetics Team, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Breast Cancer Res 9:R20. 2007....
- Multicentric breast cancer: clonality and prognostic studiesR Eeles
The Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
Breast Cancer Res Treat 129:703-16. 2011..04). In conclusion, these results suggest that a proportion of multicentric breast cancer foci are polyclonal with respect to TP53 status and that TP53 over-expression predicts for a poorer prognosis in multicentric breast cancer...
- A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practiceMichelle Ferris
Institute of Cancer Research and Royal Marsden NHS Trust, London and Sutton, Surrey, SM2 5NG, UK
Hered Cancer Clin Pract 5:157-60. 2007..This is the first general practice population-based study in the UK to address this issue and has implications for general practitioners who care for patients from the Ashkenazi community...
- The clinical genetics of prostate cancerSashi Kommu
Reader in Clinical Cancer Genetics, Translational Cancer Genetics Team, Institute of Cancer Research, Sutton, UK
Hered Cancer Clin Pract 2:111-21. 2004..Finally, current and future management strategies of men with Hereditary Prostate Cancer (HPC) are discussed...
- Multiple newly identified loci associated with prostate cancer susceptibilityRosalind A Eeles
The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
Nat Genet 40:316-21. 2008..7 x 10(-29)). We confirmed previous reports of common loci associated with prostate cancer at 8q24 and 17q. Moreover, we found that three of the newly identified loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK3...
- Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United KingdomSusan Shanley
Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
Clin Cancer Res 12:7033-8. 2006..To evaluate acute toxicity induced by chemotherapy for breast cancer in a retrospective study of 62 BRCA1/2 mutation carriers matched 1:1 with women who had treatment for sporadic disease in the United Kingdom between 1983 and 2003...
- Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancerSameer Jhavar
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey, UK
BJU Int 103:1256-69. 2009....
- Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United KingdomSusan Shanley
Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK
Clin Cancer Res 12:7025-32. 2006..To undertake the first substantial clinical study of breast radiotherapy toxicity in BRCA1 and BRCA2 mutation carriers in the United Kingdom...
- Overexpression of RAD51 occurs in aggressive prostatic cancerAnita Mitra
Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Histopathology 55:696-704. 2009..To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes...
- The genetic epidemiology of prostate cancer and its clinical implicationsRosalind Eeles
Oncogenetics team, Division of Cancer Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
Nat Rev Urol 11:18-31. 2014..However, risk modelling and clinical translational research are needed before we can translate risk profiles generated from these variants into use in the clinical setting for targeted screening and treatment. ..
- Identification of four new susceptibility loci for testicular germ cell tumourKevin Litchfield
Division of Genetics and Epidemiology, The Institute of Cancer Research, London SM2 5NG, UK
Nat Commun 6:8690. 2015..These findings provide additional support for a polygenic model of TGCT risk and further insight into the biological basis of disease development. ..
- Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerElena Castro
Prostate Cancer Unit, Clinical Research Programme, Spanish National Cancer Research Centre CNIO, Madrid, Spain Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, UK Electronic address
Eur Urol 68:186-93. 2015..Germline BRCA mutations are associated with worse prostate cancer (PCa) outcomes; however, the most appropriate management for mutation carriers has not yet been investigated...
- Ductal approaches to assessment and management of women at high risk for developing breast cancerImogen Locke
Translational Cancer Genetics Team and Cancer Genetics Unit, The Institute of Cancer Research and The Royal Marsden NHS Trust, Sutton, Surrey, UK
Breast Cancer Res 6:75-81. 2004..The small quantities of nipple aspiration fluid available for analysis, and difficulties identifying and cannulating ducts remain important limitations of these techniques...
- Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier statusZsofia Kote-Jarai
Translational Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
Clin Cancer Res 10:958-63. 2004..The impact of the presence of a germ-line BRCA1 mutation on gene expression in normal breast fibroblasts after radiation-induced DNA damage has been investigated...
- Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damageZsofia Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Clin Cancer Res 12:3896-901. 2006..We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells...
- Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk menEmma Killick
Institute of Cancer Research, Sutton, Surrey, UK
Sci Rep 3:2059. 2013..Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals. ..
- The role of BRCA1 and BRCA2 in prostate cancerElena Castro
Oncogenetics team, The Institute of Cancer Research, Sutton, UK
Asian J Androl 14:409-14. 2012..We will also discuss the implications of these mutations in the management of prostate cancer and hypothesize on the potential for the development of strategies for sporadic cases with similar characteristics...
- Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyondChristos Mikropoulos
The Institute of Cancer Research, Sutton, Surrey, UK
Future Oncol 10:1679-94. 2014..Based on the combined risk of the 78 SNPs identified so far, the top 1% of the risk distribution has a 4.7-times higher risk of developing PrCa compared with the average of the general population. ..
- Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activationNayanta Sodha
Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Cancer Res 66:8966-70. 2006..In addition, the results imply that these mutations, as well as 1100delC, cannot act in a dominant-negative manner to cause cancer, and tumorigenesis in association with these mutations may be due to haploinsufficiency...
- Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14Elise Ruark
Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, UK
Nat Genet 45:686-9. 2013..3, is required for the regulation of germ cell development. Furthermore, PITX1, at 5q31.1, regulates TERT expression and is the third TGCT-associated locus implicated in telomerase regulation...
- Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arraysSameer Jhavar
Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, Surrey SM2 5NG, UK
J Mol Diagn 10:50-7. 2008..These studies demonstrate that expression analyses using exon arrays represent a valuable approach for detecting ETS gene translocation in prostate cancer, in parallel with analyses of gene expression profiles...
- Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25Kevin Litchfield
Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK
Hum Mol Genet 24:1169-76. 2015..31 (rs1510272) demonstrating association with TGCT [per-allele odds ratio (OR) = 1.16, 95% confidence interval (CI) = 1.06-1.27; P = 1.2 × 10(-9)]. ..
- BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trialZsofia Kote-Jarai
Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
Cancer Lett 247:259-65. 2007..03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR...
- Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectivesAudrey Ardern-Jones
The Royal Marsden NHS Foundation Trust, Downs Road, Surrey, UK
Hered Cancer Clin Pract 8:1. 2010..Furthermore, there are no studies of the professional specialists who treat them - geneticists, genetic counsellors/nurses, oncologists, gynaecologists and breast surgeons...
- Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemiaMartin Yuille
Academic Department of Haematology and Cytogenetics, and the Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
Blood 99:4216-8. 2002..04). The risk of CLL associated with possession of all 3 "high-risk" genotypes was increased 2.8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL...
- Outcome of early detection and radiotherapy for occult spinal cord compressionRamachandran Venkitaraman
Academic Urology Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK
Radiother Oncol 85:469-72. 2007..Thus MRI surveillance for SCC may be important for prostate cancer patients with bone metastases...
- Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic"Audrey Ardern-Jones
The Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, UK
Hered Cancer Clin Pract 2:77-9. 2004..This case illustrates the work of the multi-disciplinary team caring for BRCA carriers...
- Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal womenJillian Noble
Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
Breast Cancer Res Treat 104:191-6. 2007....
- Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatmentJulie Shorrocks
Department of Biological Sciences, Institute of Environmental and Natural Sciences, Lancaster University, Lancaster LA1 4YQ, UK
Int J Radiat Oncol Biol Phys 58:470-8. 2004..Here the response to the three forms of cellular stress was examined in primary human fibroblasts from individuals with a +/+ or +/- genotype for BRCA1...
- Mutations in BRCA1 and BRCA2 and predisposition to prostate cancerMarc Tischkowitz
Lancet 362:80; author reply 80. 2003
- Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriersGillian Mitchell
Translational Cancer Genetics Team, Institute of Cancer Research and Cancer Genetics Unit, Royal Marsden NHS Hospital, United Kingdom
Cancer Res 66:1866-72. 2006..Use of mammographic density could improve individual risk prediction in carriers...
- Early outcomes of active surveillance for localized prostate cancerClaire Hardie
Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
BJU Int 95:956-60. 2005....
- Optimizing the diagnosis of prostate cancer in high-risk men: the supplementary biomarker approachSashi Kommu
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, UK
BJU Int 95:5-7. 2005
- Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinicKathleen Lintz
Institute of Cancer Research, Sutton, England, UK
Psychooncology 12:769-83. 2003..Although most men with prostate cancer seem to function quite well, a substantial minority report areas of unmet need that may be targets for improving care...
- Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their familyNina Hallowell
Public Health Sciences, The Medical School, University of Edinburgh, and Western Australia Centre for Cancer and Palliative Care Research, Perth, UK
Sociol Health Illn 28:969-88. 2006..It is argued that narrative reconstruction enables these men to reconcile their genetic identity, self and family...
- Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer GeneticsNicola J Camp
University of Utah ICPCG Group and Division of Genetic Epidemiology, University of Utah School of Medicine, 391 Chipeta Way, Suite D, Salt Lake City, UT 84108, USA
Hum Mol Genet 16:1271-8. 2007..This collaborative study by the ICPCG illustrates the value of consortium efforts and the continued utility of linkage analysis using informative pedigrees to localize genes for complex diseases...
- Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)Johanne Geary
Department of Medical Genetics, St George s University of London, Cranmer Terrace, London SW17 0RE, UK
Fam Cancer 7:163-72. 2008..Breast cancer RR was 1.7 overall. The type of mutation (truncating or other type, and site of mutation) showed no obvious correlation with the presence or absence of extra-colonic cancers in families...
- Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyRoy Vergis
Institute of Cancer Research, Sutton, UK
Lancet Oncol 9:342-51. 2008..We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically...
- A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imagingMichael Khazen
Institute of Cancer Research, United Kingdom
Cancer Epidemiol Biomarkers Prev 17:2268-74. 2008..A method and computer tool to estimate percentage magnetic resonance (MR) imaging (MRI) breast density using three-dimensional T(1)-weighted MRI is introduced, and compared with mammographic percentage density [X-ray mammography (XRM)]...